Sign up USA
Proactive Investors - Run By Investors For Investors

PreveCeutical Medical shareholders approve 5:1 stocks split

Shareholders approved the move at the AGM and special meeting of shareholders on May 14
boardroom
Chairman Stephen Van Deventer.said it would make shares more accessible and enhance liquidity

Health sciences and preventative medicines firm PreveCeutical Medical Inc (CSE:PREV, OTCQB:PRVCF) is poised to carry out a stock split after shareholders approved the plan.

At the AGM and special meeting of shareholders on May 14, a special resolution was passed approving the proposed split on the basis of five new shares for each one existing (5:1).

READ: PreveCeutical Medical receives second Aurora cannabis shipment

"We believe the stock split demonstrates the company's continued commitment to broaden its shareholder base and we anticipate that the stock split will make PreveCeutical's securities more accessible to investors and enhance liquidity for shareholders." said president and chairman Stephen Van Deventer.

Earlier this month, the firm said it had received the second shipment of dried cannabis materials from major Aurora Cannabis, which will be used in PreveCeutical's soluble gel (Sol-gel) drug delivery research.

As revealed in March, the company, in a major milestone, had received the key permits to allow this material to be imported into Australia by the cannabis major.

It is being used for the group's research led by Preveceutical's chief research officer Dr Harendra Parekh at the University of Queensland.

Preveceutical aims to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
mri scanner
June 06 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use